Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna Inc

FDA Committee Backs Moderna's COVID-19 Shot For Kids, Adolescents: Report

Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine received unanimous backing from the FDA's committee of independent immunization experts for children ages 6 through 17.

Benzinga

EU Urges Pfizer To Further Delay COVID-19 Vaccine Deliveries: Reuters

Amid lower demand, Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) agreed to delay supplies of their Covid-19 shot to the European Union. Doses to be shipped from June to August would be sent in September and Q4. Reuters reports that the bloc is putting heat on Pfizer to restrict supplies further. The move comes two weeks after…

Benzinga

Moderna's COVID-19 Shot Likely Related To Higher Heart Inflammation Risk Than Pfizer's: Reuters

Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccine may relate to a higher risk of heart inflammation in some age groups than Pfizer Inc (NYSE:PFE) - BioNTech SE's (NASDAQ:BNTX) shot, Reuters reported citing the Centers for Disease Control and Prevention. Citing recent data, CDC said that the findings on myocarditis and pericarditis, types of heart inflammation linked to both the…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna shot 'works in kids 6 months and up'

Moderna Inc's Covid-19 vaccine is effective in children and adolescents, with mostly mild to moderate side effects, the United States Food and Drug Administration staff said.

Bangkok Post

Moderna data show vaccine works in kids 6 months and up, FDA says

Moderna Inc.’s COVID-19 vaccine is effective in children and adolescents, with mostly mild to moderate side effects, the U.S. Food and Drug Administration staff said.

Tribune News Service

Moderna’s omicron-targeted shot bolsters antibodies in trial

Moderna Inc. said its COVID-19 vaccine that targets omicron generated a “superior” immune response against the variant compared to its original shot in a widely awaited study that could pave the way for another round of boosters in the fall.

Tribune News Service

Moderna's Updated COVID-19 Shot Boosts Omicron Protection

Moderna Inc (NASDAQ: MRNA) has

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Moderna says Omicron-targeted COVID shot shows better response

Moderna Inc said on Wednesday a new version of its coronavirus vaccine produced a better immune response against Omicron than the original shot, as the drugmaker pursues a booster against a surge in infections in the fall season.

Reuters

Moderna delays COVID vaccine deliveries to EU by several months

Moderna Inc said on Thursday it has agreed to push back some COVID-19 vaccine deliveries to the European Union by several months to later in 2022 or early next year.

Reuters

Japan study shows women more likely to get skin rash from Moderna shot

A study in Japan found that women were significantly more likely than men to develop rash-like side effects after a first dose of Moderna Inc's COVID-19 vaccine.

Reuters

This Famed Company Is Working On A Potential Monkeypox Vaccine

As cases of monkeypox continue to rise, Moderna Inc (NASDAQ: MRNA) is probably working on its platform towards finding a vaccine shot against the disease.

Benzinga

Moderna's Chairman Defends Executive Hiring Process After Firing New CFO In Just One Day

Moderna Inc’s (NASDAQ: MRNA) chairman comes forward with a determined defense of the board’s executive hiring process after being forced to fire its new chief financial officer just a day after taking charge.

Benzinga

Biden Says US Ready To Share COVID-19 Vaccine Related Technology

President Joe Biden said that the U.S. will share technologies used to make COVID-19 vaccines through the World Health Organization and is working on expanding rapid testing and antiviral treatments for hard-to-reach populations. "We are making available health technologies that are owned by the United States government, including stabilized spike protein that…

Benzinga

Moderna Concludes FDA Submission For Its COVID-19 Shot In Adolescents, Kids

Reuters reported that Moderna Inc (NASDAQ:MRNA) had made required submissions to the FDA for emergency use authorization of its COVID-19 vaccine in adolescents and children. An advisory panel of experts to the U.S. drug regulator will meet in June to review the request. Related: FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Did Moderna CFO Exit Just A Day After Taking Charge

Moderna Inc (NASDAQ:MRNA) announced that its recently appointed Chief Financial Officer, Jorge Gomez, has departed the company, effective immediately. The announcement follows the public disclosure by Gomez's former employer, Dentsply Sirona Inc (NASDAQ:XRAY), of an ongoing internal investigation into some issues, including financial reporting. The audit investigates Dentsply Sirona's "use of incentives to sell products to…

Benzinga

Why Moderna Shares Are Trading Lower Following Novavax's Earnings Report

Moderna Inc (NASDAQ: MRNA) shares are trading lower by 3.15% at $131.52.

Benzinga

Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ

Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking royalties from the federal government.

Benzinga

Here's Why Moderna Shares Are Trading Higher After Q1 Earnings Today

Moderna Inc (NASDAQ:MRNA) reports a Q1 EPS of $8.58, compared to the $2.84 posted a year ago, handsomely beating the consensus estimate of $5.21. Total revenue was $6.1 billion compared to $1.9 billion in Q1 FY21, primarily due to increased product sales. The revenue consensus was $4.43 billion. Product sales were $5.9…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Moderna Bullish On COVID-19 Vaccine For Younger Kids To Be Ready Next Month: Reuters

Moderna Inc's (NASDAQ:MRNA) chief medical officer said that its COVID-19 vaccine for children under six years old would be ready for review by the FDA panel when it meets in June. "I think the FDA now has all of the core fundamental data they need to be able to begin an application review.…

Benzinga

FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For Kids, Plus Novavax EUA

The FDA has set up June meeting dates to review COVID-19 vaccine submissions, noting that the dates are tentative as none of the submissions are complete. The agency reserved June 8, 21, and 22 for virtual meetings of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) to review Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE)…

Benzinga

Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6 Years

Moderna Inc (NASDAQ: MRNA)

Tribune News Service

Moderna applies for US clearance of COVID shot for young kids

Moderna Inc. applied for emergency use authorization for its COVID-19 vaccine in children from six months to under 6 years old after a successful trial showed two doses generate high levels of antibodies to the virus.

Benzinga

Analyzing Moderna Inc's Short Interest

Moderna Inc's (NASDAQ:MRNA) short percent of float has fallen 6.25% since its last report. The company recently reported that it has 16.21 million shares sold short, which is 4.65% of all regular shares that are available for trading.

Benzinga

Poland, Moderna Working Towards Increased Flexibility Of COVID-19 Vaccine Contracts: Reuters

Poland can compromise with Moderna Inc (NASDAQ:MRNA) on increasing the flexibility of COVID-19 vaccine contracts, Reuters reported citing the health minister, striking an upbeat tone after initial talks with the company. Poland has said it will not take or pay for more doses of the COVID-19 vaccine under the European Union's supply contract. Reuters…

Benzinga

What's Going On With Moderna Shares?

Shares of vaccine companies, including Moderna Inc (NASDAQ: MRNA), are trading higher amid COVID-19 concerns due to rising cases in China.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Food and Drug Administration

315 stories

Pfizer Inc

304 stories

Centers for Disease Control and Prevention

299 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.